182 related articles for article (PubMed ID: 28750090)
1. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA
PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.
Xiao H; Bid HK; Jou D; Wu X; Yu W; Li C; Houghton PJ; Lin J
J Biol Chem; 2015 Feb; 290(6):3418-29. PubMed ID: 25313399
[TBL] [Abstract][Full Text] [Related]
3. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.
Zhao C; Wang W; Yu W; Jou D; Wang Y; Ma H; Xiao H; Qin H; Zhang C; Lü J; Li S; Li C; Lin J; Lin L
Oncotarget; 2016 Mar; 7(11):12917-26. PubMed ID: 26883202
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
6. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
7. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
[TBL] [Abstract][Full Text] [Related]
8. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
Chen CL; Loy A; Cen L; Chan C; Hsieh FC; Cheng G; Wu B; Qualman SJ; Kunisada K; Yamauchi-Takihara K; Lin J
BMC Cancer; 2007 Jun; 7():111. PubMed ID: 17598902
[TBL] [Abstract][Full Text] [Related]
10. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
[TBL] [Abstract][Full Text] [Related]
11. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
12. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.
Wu X; Xiao H; Wang R; Liu L; Li C; Lin J
Curr Cancer Drug Targets; 2016; 16(7):631-8. PubMed ID: 26373715
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
Bid HK; Oswald D; Li C; London CA; Lin J; Houghton PJ
PLoS One; 2012; 7(4):e35513. PubMed ID: 22530037
[TBL] [Abstract][Full Text] [Related]
14. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Garofalo C; Capristo M; Manara MC; Mancarella C; Landuzzi L; Belfiore A; Lollini PL; Picci P; Scotlandi K
PLoS One; 2013; 8(12):e83832. PubMed ID: 24391834
[TBL] [Abstract][Full Text] [Related]
15. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
16. Characterization of STAT3 activation and expression in canine and human osteosarcoma.
Fossey SL; Liao AT; McCleese JK; Bear MD; Lin J; Li PK; Kisseberth WC; London CA
BMC Cancer; 2009 Mar; 9():81. PubMed ID: 19284568
[TBL] [Abstract][Full Text] [Related]
17. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
18. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
19. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
20. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
